How pharmaceutical brands can be resilient

While inflation and economic pressures force pharmaceutical brands to watch their pennies, they will do well to not tackle cost efficiency as a solo issue. Brands require resilience in various areas, and chief among these is compliance. Stringent regulations must be followed, although the supply chains from which they are navigated, are incredibly complex.

So, can brands manage resilience factors, such as costs and compliance, holistically? Supplier expert and HICX’s CEO, Costas Xyloyiannis, says they can in an Expert View column.

My view is that on the one hand, each factor has unique requirements, such as finding ways to cut costs or to stop risky activities. However, each factor stems from a common cause: murky supply chains. By fixing poor-quality supplier data, therefore, brands can empower themselves to be robust.